MedTrace Logo

A Study About Nutritional Support of Enhanced Protein in Critical Patients

NCT04177446 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2019-12-20

No results posted yet for this study

Summary

This is a prospective randomized controlled trial. 180 patients with critical illness will be included and randomly divided into two groups. In the control group, patients will be fed with basic energy; and in the experiment group, the patients will be given extra protein intake except the basic energy intake. The intervention duration will last 6 days. The primary outcomes of this study are urea nitrogen of 24h and prealbumin(PA). And other outcomes include nutritional status, safety indicators and clinical indicators.

Conditions

  • Critical Illness

Interventions

DIETARY_SUPPLEMENT

a production consist of various oligopeptides and the whey protein

patients will be given extra protein intake except the basic energy intake

DIETARY_SUPPLEMENT

basic energy intake

supplement as basic energy intake

DIETARY_SUPPLEMENT

maltodextrin

used as placebo in the control group

Sponsors & Collaborators

  • Yabao Pharmaceutical Group

    collaborator INDUSTRY

  • The First Affiliated Hospital of Dalian Medical University

    collaborator OTHER

  • The Second Affiliated Hospital of Dalian Medical University

    collaborator OTHER

  • First Affiliated Hospital Xi'an Jiaotong University

    collaborator OTHER

  • The First Affiliated Hospital of Zhengzhou University

    collaborator OTHER

  • Peking Union Medical College Hospital

    lead OTHER

Principal Investigators

  • Wei Chen · Peking Union Medical College Hospital

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-25
Primary Completion
2020-05-31
Completion
2020-05-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04177446 on ClinicalTrials.gov